FOR TRANSLATIONAL RESEARCH IN NUCLEAR MEDICINE
Arronax Nantes brings together all stakeholders in Nantes working on research and development in nuclear medicine.
This more particularly include the GIP ARRONAX, the laboratories Ceisam, CEMA-Oniris, CRCI2NA, LS2N, Subatech, the CRIP-Oniris core facility and the Nuclear Medicine departments of the University Hospital of Nantes and the ICO.
Arronax Nantes is a stakeholder in the I-SITE NExT, in close collaboration with the LabEx IRON and the SIRIC ILIAD.
our publications
Methodology for small animals targeted irradiations at conventional and ultra-high dose rates 65 MeV proton beam, Evin M, Koumeir C, Bongrand A, Delpon G, Haddad F, Mouchard Q, et al., Physica Medica., 1 avr 2024;120:103332. https://doi.org/10.1016/j.ejmp.2024.103332
Validation of the ΔSUVmax for interim PET interpretation in diffuse large B-cell lymphoma on the basis of the GAINED clinical study. Itti E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, Kraeber-Bodéré F, Meignan M, Gat E, Le Gouill S, Casasnovas RO, Bodet-Milin C. J Nucl Med. 2023, 64: 1706-1711. https://doi.org/10.2967/jnumed.123.265871
our news
Vanessa targeting terbium production 155
29/02/24
Oncology: Arronax provides doses for an innovative clinical trial in alpha therapy
06/02/24
ISI NucMed 2024 : registration is now open!
06/02/24![[Save the date] LabEx IRON day: 13 years of success!](/wp-content/uploads/2023/12/banner-IRON-2024-270x200.png)
[Save the date] LabEx IRON day: 13 years of success!
05/12/23
Fatima uses algorithms to track cyclotron anomalies
29/11/23
ISI NucMed thematic school is back in 2024
16/11/23Our equipments
